Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.

Bibliographic Details
Title: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
Authors: Hahné, Susan Jm (AUTHOR), Veldhuijzen, Irene K (AUTHOR), Wiessing, Lucas (AUTHOR), Lim, Tek-Ang (AUTHOR), Salminen, Mika (AUTHOR), Laar, Marita van de (AUTHOR), Hahné, Susan J M1 (AUTHOR)
Source: BMC Infectious Diseases. 2013, Vol. 13 Issue 1, p181-181. 1p.
Abstract: Background: Treatment for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is improving but not benefiting individuals unaware to be infected. To inform screening policies we assessed (1) the hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCV-Ab) prevalence for 34 European countries; and (2) the cost-effectiveness of screening for chronic HBV and HCV infection.Methods: We searched peer-reviewed literature for data on HBsAg and anti-HCV-Ab prevalence and cost-effectiveness of screening of the general population and five subgroups, and used data for people who inject drugs (PWID) and blood donors from two European organizations. Of 1759 and 468 papers found in the prevalence and cost-effectiveness searches respectively, we included 124 and 29 papers after assessing their quality. We used decision rules to calculate weighted prevalence estimates by country.Results: The HBsAg and anti-HCV-Ab prevalence in the general population ranged from 0.1%-5.6% and 0.4%-5.2% respectively, by country. For PWID, men who have sex with men and migrants, the prevalence of HBsAg and anti-HCV-Ab was higher than the prevalence in the general population in all but 3 countries. There is evidence that HCV screening of PWID and HBsAg screening of pregnant women and migrants is cost-effective.Conclusion: The prevalence of chronic HBV and HCV infection varies widely between European countries. Anti-HCV-Ab screening of PWID and HBsAg screening of pregnant women and migrants have European public health priority. Cost-effectiveness analyses may need to take effect of antiviral treatment on preventing HBV and HCV transmission into account. [ABSTRACT FROM AUTHOR]
Copyright of BMC Infectious Diseases is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:a9h&genre=article&issn=14712334&ISBN=&volume=13&issue=1&date=20130101&spage=181&pages=181-181&title=BMC Infectious Diseases&atitle=Infection%20with%20hepatitis%20B%20and%20C%20virus%20in%20Europe%3A%20a%20systematic%20review%20of%20prevalence%20and%20cost-effectiveness%20of%20screening.&aulast=Hahn%C3%A9%2C%20Susan%20Jm&id=DOI:10.1186/1471-2334-13-181
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
Header DbId: a9h
DbLabel: Academic Search Complete
An: 104038565
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hahné%2C+Susan+Jm%22">Hahné, Susan Jm</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Veldhuijzen%2C+Irene+K%22">Veldhuijzen, Irene K</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wiessing%2C+Lucas%22">Wiessing, Lucas</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lim%2C+Tek-Ang%22">Lim, Tek-Ang</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Salminen%2C+Mika%22">Salminen, Mika</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Laar%2C+Marita+van+de%22">Laar, Marita van de</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hahné%2C+Susan+J+M%22">Hahné, Susan J M</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22BMC+Infectious+Diseases%22">BMC Infectious Diseases</searchLink>. 2013, Vol. 13 Issue 1, p181-181. 1p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Treatment for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is improving but not benefiting individuals unaware to be infected. To inform screening policies we assessed (1) the hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCV-Ab) prevalence for 34 European countries; and (2) the cost-effectiveness of screening for chronic HBV and HCV infection.<bold>Methods: </bold>We searched peer-reviewed literature for data on HBsAg and anti-HCV-Ab prevalence and cost-effectiveness of screening of the general population and five subgroups, and used data for people who inject drugs (PWID) and blood donors from two European organizations. Of 1759 and 468 papers found in the prevalence and cost-effectiveness searches respectively, we included 124 and 29 papers after assessing their quality. We used decision rules to calculate weighted prevalence estimates by country.<bold>Results: </bold>The HBsAg and anti-HCV-Ab prevalence in the general population ranged from 0.1%-5.6% and 0.4%-5.2% respectively, by country. For PWID, men who have sex with men and migrants, the prevalence of HBsAg and anti-HCV-Ab was higher than the prevalence in the general population in all but 3 countries. There is evidence that HCV screening of PWID and HBsAg screening of pregnant women and migrants is cost-effective.<bold>Conclusion: </bold>The prevalence of chronic HBV and HCV infection varies widely between European countries. Anti-HCV-Ab screening of PWID and HBsAg screening of pregnant women and migrants have European public health priority. Cost-effectiveness analyses may need to take effect of antiviral treatment on preventing HBV and HCV transmission into account. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of BMC Infectious Diseases is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=a9h&AN=104038565
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/1471-2334-13-181
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: 181
    Titles:
      – TitleFull: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hahné, Susan Jm
      – PersonEntity:
          Name:
            NameFull: Veldhuijzen, Irene K
      – PersonEntity:
          Name:
            NameFull: Wiessing, Lucas
      – PersonEntity:
          Name:
            NameFull: Lim, Tek-Ang
      – PersonEntity:
          Name:
            NameFull: Salminen, Mika
      – PersonEntity:
          Name:
            NameFull: Laar, Marita van de
      – PersonEntity:
          Name:
            NameFull: Hahné, Susan J M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2013
              Type: published
              Y: 2013
          Identifiers:
            – Type: issn-print
              Value: 14712334
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC Infectious Diseases
              Type: main
ResultId 1